{"protocolSection":{"identificationModule":{"nctId":"NCT01351415","orgStudyIdInfo":{"id":"MO22097"},"secondaryIdInfos":[{"id":"2010-022645-14","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)","officialTitle":"An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy"},"statusModule":{"statusVerifiedDate":"2017-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-06-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-06-25","type":"ACTUAL"},"completionDateStruct":{"date":"2016-06-25","type":"ACTUAL"},"studyFirstSubmitDate":"2011-05-09","studyFirstSubmitQcDate":"2011-05-09","studyFirstPostDateStruct":{"date":"2011-05-10","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-06-20","resultsFirstSubmitQcDate":"2017-08-17","resultsFirstPostDateStruct":{"date":"2017-09-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2017-08-17","lastUpdatePostDateStruct":{"date":"2017-09-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC. Participants will be enrolled at documentation of progression of disease (PD) after 4-6 cycles of first-line treatment with bevacizumab plus a platinum doublet-containing therapy and a minimum of two cycles of bevacizumab maintenance treatment prior to PD. Participants will be randomly assigned to one of two treatment arms to receive either bevacizumab plus SOC treatment or SOC treatment alone."},"conditionsModule":{"conditions":["Non-Squamous Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":485,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Bevacizumab + Standard of Care","type":"EXPERIMENTAL","description":"Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).","interventionNames":["Drug: Bevacizumab","Drug: Docetaxel","Drug: Erlotinib","Drug: Pemetrexed"]},{"label":"Standard of Care","type":"ACTIVE_COMPARATOR","description":"Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).","interventionNames":["Drug: Docetaxel","Drug: Erlotinib","Drug: Pemetrexed"]}],"interventions":[{"type":"DRUG","name":"Bevacizumab","description":"Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.","armGroupLabels":["Bevacizumab + Standard of Care"],"otherNames":["Avastin"]},{"type":"DRUG","name":"Docetaxel","description":"Docetaxel 60 or 75 milligram per meter square (mg/m\\^2) on Day 1 every 21 days.","armGroupLabels":["Bevacizumab + Standard of Care","Standard of Care"]},{"type":"DRUG","name":"Erlotinib","description":"Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.","armGroupLabels":["Bevacizumab + Standard of Care","Standard of Care"]},{"type":"DRUG","name":"Pemetrexed","description":"Pemetrexed 500 mg/m\\^2 IV over 10 minutes on Day 1 every 21 days.","armGroupLabels":["Bevacizumab + Standard of Care","Standard of Care"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival (OS)","description":"Overall survival (OS) was defined as the time from the date of randomization at first progression of disease to the date of death, regardless of the cause of death.","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)"}],"secondaryOutcomes":[{"measure":"Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)","description":"PFS was defined as the time from start of treatment to the first event of death or PD. Tumor response was assessed by the IRF according to RECIST v1.1. Disease progression or PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS2 is defined as the time between randomization at PD1 and the date of PD2 or death, whichever occurs first. PFS3 is defined as the time between PD2 and the date of PD3 or death, whichever occurs first.","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)"},{"measure":"Percentage of Participants With Objective Response According to RECIST v1.1","description":"The objective response is defined as complete response (CR) or partial response (PR) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR was defined as greater than or equal to (≥) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR.","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)"},{"measure":"Percentage of Participants With Disease Control According to RECIST v1.1","description":"The disease control rate is defined as CR or PR or stable disease (SD) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started for target lesions and the persistence of 1 or more non-target lesions.","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)"},{"measure":"Duration of Response (DoR) According to RECIST v1.1","description":"Duration of response is defined as the time that measurement criteria are met for objective response (CR/PR) (whichever status is recorded first) until the first date of progression or death is documented. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \\< 10 mm. PR was defined as greater than or equal to ≥30 % decrease in sum of longest diameter of target lesions in reference to baseline sum longest diameter.","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)"},{"measure":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)"},{"measure":"Time to Progression (TTP) According to RECIST v1.1","description":"The time to progression was defined as the time from baseline until disease progression as determined by the RECIST v1.1. TTP2 is defined as the interval between the day of randomization at PD1 and PD2. TTP3 is defined as the interval between the day of PD2 and PD3. PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)"},{"measure":"Percentage of Participants Who Are Alive at Month 6, 12, and 18","description":"Percentage of participants who were alive at Month 6, 12 and 18 were reported.","timeFrame":"Month 6, 12, 18"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed non-squamous NSCLC\n* Documented progression of disease (locally recurrent or metastatic) per investigator assessment following first-line treatment with 4-6 cycles of Bevacizumab plus a platinum doublet-containing chemotherapy regimen and a minimum of 2 cycles of Bevacizumab (monotherapy) maintenance treatment prior to first progression of disease\n* No treatment interruption of Bevacizumab treatment greater than 2 consecutive cycles (42 days) between the start of first-line treatment to start of Cycle 1 of second line treatment\n* Randomization within 4 weeks of progression of disease\n* At least one unidimensionally measurable lesion meeting RECIST v1.1 criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Participants with adequate hematological, liver, and renal function\n* Female participants must not be pregnant or breast-feeding. Female participants of childbearing potential and fertile male participants must agree to use a highly effective contraceptive during the trial and for a period of at least 6 months following the last administration of trial drug(s)\n\nExclusion Criteria:\n\n* Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component\n* Epidermal growth factor receptor (EGFR)-mutation-positive disease according to local laboratory testing\n* History of hemoptysis greater than or equal to (\\>/=) grade 2 within 3 months of randomization\n* History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding and active gastrointestinal bleeding\n* Major cardiac disease\n* Treatment with any other investigational agent within 28 days prior to randomization\n* Known hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs foreseen\n* Malignancy other than NSCLC within 5 years prior to randomization and evidence of any other disease that contraindicates the use of an investigational or SOC drug","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"USA Mitchell Cancer Institute","city":"Mobile","state":"Alabama","zip":"36688","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Palo Verde Hema/Onc","city":"Glendale","state":"Arizona","zip":"85304","country":"United States","geoPoint":{"lat":33.53865,"lon":-112.18599}},{"facility":"Arizona Center for Cancer Care","city":"Glendale","state":"Arizona","zip":"85306","country":"United States","geoPoint":{"lat":33.53865,"lon":-112.18599}},{"facility":"Clopton Clinic","city":"Jonesboro","state":"Arkansas","zip":"72401","country":"United States","geoPoint":{"lat":35.8423,"lon":-90.70428}},{"facility":"East Valley Hematology ; Oncology Medical Group","city":"Burbank","state":"California","zip":"91505","country":"United States","geoPoint":{"lat":34.18084,"lon":-118.30897}},{"facility":"California Cancer Associates for Research & Excellence, Inc.","city":"Encinitas","state":"California","zip":"92008","country":"United States","geoPoint":{"lat":33.03699,"lon":-117.29198}},{"facility":"Scripps Clinic; Hematology & Oncology","city":"La Jolla","state":"California","zip":"92037-1027","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Sutter Cancer Center","city":"Sacramento","state":"California","zip":"95816","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Coastal Integrative Cancer Care","city":"San Luis Obispo","state":"California","zip":"93401","country":"United States","geoPoint":{"lat":35.28275,"lon":-120.65962}},{"facility":"Innovative Clinical Research Institute","city":"Whittier","state":"California","zip":"90603","country":"United States","geoPoint":{"lat":33.97918,"lon":-118.03284}},{"facility":"The Hospital of Central CT","city":"New Britain","state":"Connecticut","zip":"06050","country":"United States","geoPoint":{"lat":41.66121,"lon":-72.77954}},{"facility":"Eastern Ct Hema/Onco Assoc; Dept of Oncology","city":"Norwich","state":"Connecticut","zip":"06360","country":"United States","geoPoint":{"lat":41.52426,"lon":-72.07591}},{"facility":"Lynn Cancer Institute - West","city":"Boca Raton","state":"Florida","zip":"33428","country":"United States","geoPoint":{"lat":26.35869,"lon":-80.0831}},{"facility":"Baptist - MD Anderson Cancer Center","city":"Jacksonville","state":"Florida","zip":"32207","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Mount Sinai Medical Center","city":"Miami Beach","state":"Florida","zip":"33140","country":"United States","geoPoint":{"lat":25.79065,"lon":-80.13005}},{"facility":"Cancer Care Centers of Brevard","city":"Rockledge","state":"Florida","zip":"32955","country":"United States","geoPoint":{"lat":28.35084,"lon":-80.72533}},{"facility":"Emory Univ Winship Cancer Inst","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Summit Cancer Care PC","city":"Savannah","state":"Georgia","zip":"31405","country":"United States","geoPoint":{"lat":32.08354,"lon":-81.09983}},{"facility":"Kootenai Cancer Center","city":"Post Falls","state":"Idaho","zip":"83854","country":"United States","geoPoint":{"lat":47.71796,"lon":-116.95159}},{"facility":"Alexian Brothers Neurosci Inst","city":"Elk Grove Village","state":"Illinois","zip":"60007","country":"United States","geoPoint":{"lat":42.00392,"lon":-87.97035}},{"facility":"Oncology-Evanston Nthwest Healthcare Kellogg Cancer Care Ctr","city":"Evanston","state":"Illinois","zip":"60201","country":"United States","geoPoint":{"lat":42.04114,"lon":-87.69006}},{"facility":"Joliet Oncology Hematology Associates, Ltd.","city":"Joliet","state":"Illinois","zip":"60435","country":"United States","geoPoint":{"lat":41.52519,"lon":-88.0834}},{"facility":"Cancer Care & Hematology; Specialists of Chicagoland","city":"Niles","state":"Illinois","zip":"60714","country":"United States","geoPoint":{"lat":42.01892,"lon":-87.80284}},{"facility":"W. Suburban Ctr for Cncer Care","city":"River Forest","state":"Illinois","zip":"60305","country":"United States","geoPoint":{"lat":41.89781,"lon":-87.81395}},{"facility":"St. Francis Medical Group","city":"Indianapolis","state":"Indiana","zip":"46237","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Oncology Hematology Associates of Southwest Indiana","city":"Newburgh","state":"Indiana","zip":"47630","country":"United States","geoPoint":{"lat":37.94449,"lon":-87.40529}},{"facility":"McFarland Clinic","city":"Ames","state":"Iowa","zip":"50010","country":"United States","geoPoint":{"lat":42.03471,"lon":-93.61994}},{"facility":"Cancer Center of Kansas","city":"Wichita","state":"Kansas","zip":"67214-3728","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"University of Kentucky Medical Center","city":"Lexington","state":"Kentucky","zip":"40536","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Jewish Cancer Care","city":"Louisville","state":"Kentucky","zip":"40245","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Hematology/Oncology Clinic, LLP","city":"Baton Rouge","state":"Louisiana","zip":"70809","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"Louisiana Oncology Associates","city":"Lafayette","state":"Louisiana","zip":"70508","country":"United States","geoPoint":{"lat":30.22409,"lon":-92.01984}},{"facility":"New England Cancer Specialists","city":"Scarborough","state":"Maine","zip":"04074","country":"United States","geoPoint":{"lat":43.57814,"lon":-70.32172}},{"facility":"York Hospital","city":"York Village","state":"Maine","zip":"03909","country":"United States","geoPoint":{"lat":43.1437,"lon":-70.65089}},{"facility":"Anne Arundel Health System Research Instit-Annapolis Oncology Ctr","city":"Annapolis","state":"Maryland","zip":"21401","country":"United States","geoPoint":{"lat":38.97859,"lon":-76.49184}},{"facility":"Tufts Medical Center; Neely Cancer Center","city":"Boston","state":"Massachusetts","zip":"02111","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Ann Arbor Hematology Oncology","city":"Ann Arbor","state":"Michigan","zip":"48106","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Henry Ford Hospital; Hematology Oncology","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Cancer & Hematology Center of West Michigan","city":"Grand Rapids","state":"Michigan","zip":"49546","country":"United States","geoPoint":{"lat":42.96336,"lon":-85.66809}},{"facility":"Metro-Minnesota CCOP","city":"Saint Louis Park","state":"Minnesota","zip":"55416","country":"United States","geoPoint":{"lat":44.9483,"lon":-93.34801}},{"facility":"St Joseph Oncology","city":"Saint Joseph","state":"Missouri","zip":"64507","country":"United States","geoPoint":{"lat":39.76861,"lon":-94.84663}},{"facility":"Heartland CCOP/Missouri Baptist Medical Center","city":"St Louis","state":"Missouri","zip":"63131","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Stony Brook Univ Cancer Ctr; Medical Oncology Clinic","city":"Stony Brook","state":"New York","zip":"11794-9447","country":"United States","geoPoint":{"lat":40.92565,"lon":-73.14094}},{"facility":"Carolina Oncology Specialists, PA - Hickory","city":"Hickory","state":"North Carolina","zip":"28602","country":"United States","geoPoint":{"lat":35.73319,"lon":-81.3412}},{"facility":"Aultman Hospital","city":"Canton","state":"Ohio","zip":"44710","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"Mid Ohio Onc Hematology Inc","city":"Columbus","state":"Ohio","zip":"43219","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Dayton Clinical Oncology Prog","city":"Dayton","state":"Ohio","zip":"45420","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"Signal Point Clinical; Research Center, LLC","city":"Middletown","state":"Ohio","zip":"45042","country":"United States","geoPoint":{"lat":39.51506,"lon":-84.39828}},{"facility":"Toledo Hospital; CCOP Toledo","city":"Toledo","state":"Ohio","zip":"43617","country":"United States","geoPoint":{"lat":41.66394,"lon":-83.55521}},{"facility":"Bay Area Hospital","city":"Coos Bay","state":"Oregon","zip":"97420","country":"United States","geoPoint":{"lat":43.3665,"lon":-124.21789}},{"facility":"St. Lukes Hospital and Health Network","city":"Bethlehem","state":"Pennsylvania","zip":"18015","country":"United States","geoPoint":{"lat":40.62593,"lon":-75.37046}},{"facility":"Hematology & Oncology Assoc; North Eastern Pennsylvania","city":"Dunmore","state":"Pennsylvania","zip":"18512","country":"United States","geoPoint":{"lat":41.4198,"lon":-75.63241}},{"facility":"St. Mary Medical Center","city":"Langhorne","state":"Pennsylvania","zip":"19047","country":"United States","geoPoint":{"lat":40.17455,"lon":-74.92267}},{"facility":"University of Pennsylvania; Radiation Oncology","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"University of Pennsylvania","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Temple University Hospital","city":"Philadelphia","state":"Pennsylvania","zip":"19140","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Lankenau Hospital","city":"Wynnewood","state":"Pennsylvania","zip":"19096","country":"United States","geoPoint":{"lat":40.00289,"lon":-75.27074}},{"facility":"Memorial Hospital of Rhode Island","city":"Pawtucket","state":"Rhode Island","zip":"02860","country":"United States","geoPoint":{"lat":41.87871,"lon":-71.38256}},{"facility":"West Clinic","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"University of Tennessee Medical Center Cancer Institute","city":"Knoxville","state":"Tennessee","zip":"37920","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Unv of TX SW Med Cntr; Hematology/Onc","city":"Dallas","state":"Texas","zip":"75390-9015","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Delta Hematology/ Oncology Associates","city":"Portsmouth","state":"Virginia","zip":"23704","country":"United States","geoPoint":{"lat":36.83543,"lon":-76.29827}},{"facility":"Blue Ridge Cancer Care - Roanoke","city":"Roanoke","state":"Virginia","zip":"24014","country":"United States","geoPoint":{"lat":37.27097,"lon":-79.94143}},{"facility":"Medical Oncology Associates","city":"Spokane","state":"Washington","zip":"99208","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"Fox Valley Hema and Onc SC","city":"Appleton","state":"Wisconsin","zip":"54915","country":"United States","geoPoint":{"lat":44.26193,"lon":-88.41538}},{"facility":"Gundersen Lutheran","city":"La Crosse","state":"Wisconsin","zip":"54601","country":"United States","geoPoint":{"lat":43.80136,"lon":-91.23958}},{"facility":"UNI OF WISCONSIN SCHOOL OF MEDICINE; GI Oncology Research Group, Paul P Carbone Cancer Center","city":"Madison","state":"Wisconsin","zip":"53792","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}},{"facility":"Inst. Alexander Fleming; Oncology Dept","city":"Buenos Aires","zip":"C1426ANZ","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Centro Oncologico Infinito; Oncologia","city":"La Pampa","zip":"6300","country":"Argentina","geoPoint":{"lat":-30.94279,"lon":-64.27622}},{"facility":"Hospital Privado de Comunidad; Oncology","city":"Mar del Plata","zip":"7600","country":"Argentina","geoPoint":{"lat":-38.00042,"lon":-57.5562}},{"facility":"Sanatorio Parque de Rosario","city":"Rosario","zip":"S2000DSV","country":"Argentina","geoPoint":{"lat":-32.94682,"lon":-60.63932}},{"facility":"ISIS Clinica Especializada","city":"Santa Fe","zip":"03000","country":"Argentina","geoPoint":{"lat":-31.64881,"lon":-60.70868}},{"facility":"Clínica Viedma","city":"Viedma, Rio Negro","zip":"8500","country":"Argentina","geoPoint":{"lat":-40.81519,"lon":-63.0004}},{"facility":"LKH Hohenems; Abteilung für Pulmologie","city":"Hohenems","zip":"6845","country":"Austria","geoPoint":{"lat":47.36121,"lon":9.68694}},{"facility":"Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie","city":"Innsbruck","zip":"6020","country":"Austria","geoPoint":{"lat":47.26266,"lon":11.39454}},{"facility":"Lkh Natters; Abt. Für Atemwegs- & Lungenkrankheiten","city":"Natters","zip":"6161","country":"Austria","geoPoint":{"lat":47.23414,"lon":11.37342}},{"facility":"A.Ö. LKH; Abt. für Lungenkrankheiten","city":"Steyr","zip":"4400","country":"Austria","geoPoint":{"lat":48.04274,"lon":14.42127}},{"facility":"Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie","city":"Vienna","zip":"1090","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Krankenhaus Der Stadt Wien Lainz; V. Medizinische Abt.","city":"Vienna","zip":"1130","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"SMZ - Baumgartner Hohe, Pavilion Leopold; 1.Interne Lungenabteilung, Onkologische Tagesklinik","city":"Vienna","zip":"1140","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Klinikum Wels-Grieskirchen; Lungenabt.","city":"Wels","zip":"4600","country":"Austria","geoPoint":{"lat":48.16667,"lon":14.03333}},{"facility":"Clin. Europe (Ste Elisabeth)","city":"Brussels","zip":"1180","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Centro de Pesquisa Clínica- Instituto do Câncer do Ceará- ICC","city":"Fortaleza","state":"Ceará","zip":"60125-120","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Nucleo de Oncologia da Bahia - NOB","city":"Salvador, Bahia","state":"Estado de Bahia","zip":"40170-380","country":"Brazil"},{"facility":"Sociedade beneficente de senhoras Hospital Sirio Libanes","city":"Brasília","state":"Federal District","zip":"70200-730","country":"Brazil","geoPoint":{"lat":-15.77972,"lon":-47.92972}},{"facility":"Centro de Estudos e Pesquisas Oncologicas - CESPO","city":"Brasília","state":"Federal District","zip":"70390-150","country":"Brazil","geoPoint":{"lat":-15.77972,"lon":-47.92972}},{"facility":"Instituto de Câncer de Brasília","city":"Taguatinga","state":"Federal District","zip":"72110-980","country":"Brazil","geoPoint":{"lat":-15.83326,"lon":-48.05506}},{"facility":"Clinicas Oncologicas Integradas - COI","city":"Rio de Janeiro","state":"Rio de Janeiro","zip":"22793-080","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Hospital de Caridade de Ijui; Oncologia","city":"Ijuí","state":"Rio Grande do Sul","zip":"98700-000","country":"Brazil","geoPoint":{"lat":-28.38778,"lon":-53.91472}},{"facility":"Clinica de Neoplasias Litoral","city":"Itajaí","state":"Santa Catarina","zip":"88301-220","country":"Brazil","geoPoint":{"lat":-26.90778,"lon":-48.66194}},{"facility":"Hospital A. C. Camargo; Oncologia","city":"São Paulo","state":"São Paulo","zip":"01509-010","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Hospital Sao Jose","city":"São Paulo","state":"São Paulo","zip":"CEP 01321-001","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Nordsjællands Hospital, Hillerød, Onkologisk Afdeling","city":"Hillerød","zip":"3400","country":"Denmark","geoPoint":{"lat":55.92791,"lon":12.30081}},{"facility":"Poly Parc Rambot La Provencale; Chimiotherapie Ambulatoire","city":"Aix-en-Provence","zip":"13617","country":"France","geoPoint":{"lat":43.5283,"lon":5.44973}},{"facility":"Centre Francois Baclesse; Oncologie","city":"Caen","zip":"14076","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Centre Hospitalier Intercommunal; Service de Pneumologie","city":"Créteil","zip":"94010","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"facility":"Hopital Nord Ouest;Unite 2c","city":"Gleizé","zip":"69400","country":"France","geoPoint":{"lat":45.98916,"lon":4.69708}},{"facility":"Centre Oscar Lambret","city":"Lille","zip":"59020","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Hopital Calmette; Pneumologie","city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Hopital Louis Pradel; Cardiologie B","city":"Lyon","zip":"69394","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Hôpital Saint Joseph; Oncologie Medicale","city":"Marseille","zip":"13285","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Hopital Nord; Service d'Oncologie Multidisciplinaire et Innovation Thérapeutique","city":"Marseille","zip":"13915","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Centre Antoine Lacassagne","city":"Nice","zip":"06189","country":"France","geoPoint":{"lat":43.70313,"lon":7.26608}},{"facility":"Ch Lyon Sud; Chir Onc Gyne Sct Jules Courmont","city":"Pierre-Bénite","zip":"69310","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"facility":"CH Rene Dubos; Oncologie","city":"Pontoise","zip":"95300","country":"France","geoPoint":{"lat":49.05,"lon":2.1}},{"facility":"Ico Rene Gauducheau; Oncologie","city":"Saint-Herblain","zip":"44805","country":"France","geoPoint":{"lat":47.21154,"lon":-1.651}},{"facility":"Institut de Cancérologie de Loire","city":"Saint-Priest-en-Jarez","zip":"42271","country":"France","geoPoint":{"lat":45.4739,"lon":4.37678}},{"facility":"Centre Paul Strauss; Oncologie Medicale","city":"Strasbourg","zip":"67065","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Hia Sainte Anne; Pneumologie","city":"Toulon","zip":"83041","country":"France","geoPoint":{"lat":43.12442,"lon":5.92836}},{"facility":"Hopital Sainte Musse; Pneumologie","city":"Toulon","zip":"83056","country":"France","geoPoint":{"lat":43.12442,"lon":5.92836}},{"facility":"Clinique Pasteur; Pneumologie","city":"Toulouse","zip":"31076","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Chi De La Haute Saone De Vesoul; Pneumologie","city":"Vesoul","zip":"70014","country":"France","geoPoint":{"lat":47.62604,"lon":6.14251}},{"facility":"Zentralklinik Bad Berka GmbH; Pneumologie","city":"Bad Berka","zip":"99437","country":"Germany","geoPoint":{"lat":50.89982,"lon":11.28245}},{"facility":"Praxis Dr. med. David Borquez","city":"Bergisch Gladbach","zip":"51465","country":"Germany","geoPoint":{"lat":50.9856,"lon":7.13298}},{"facility":"Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie","city":"Esslingen am Neckar","zip":"73730","country":"Germany","geoPoint":{"lat":48.73961,"lon":9.30473}},{"facility":"Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie","city":"Frankfurt","zip":"60488","country":"Germany","geoPoint":{"lat":49.68333,"lon":10.53333}},{"facility":"SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie","city":"Gera","zip":"07548","country":"Germany","geoPoint":{"lat":50.88029,"lon":12.08187}},{"facility":"LungenClinic Großhansdorf","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin I","city":"Halle","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"Universitaetsklinikum des Saarlandes; Innere Medizin V","city":"Homburg/Saar","zip":"66421","country":"Germany"},{"facility":"Fachklinik für Lungenerkrankungen","city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"St. Vincentius Kliniken Karlsruhe; Abteilung Hämatologie / Onkologie","city":"Karlsruhe","zip":"76137","country":"Germany","geoPoint":{"lat":49.00937,"lon":8.40444}},{"facility":"Robert-Koch-Klinik; Pneumologie","city":"Leipzig","zip":"04207","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Praxis Christian Geßner","city":"Leipzig","zip":"04357","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Johannes-Wesling-Klinikum Minden; Onkologische Ambulanz / Tagesklinik","city":"Minden","zip":"32429","country":"Germany","geoPoint":{"lat":52.28953,"lon":8.91455}},{"facility":"Ludwig-Maximilians Uni Klinik Innenstadt; Medizinische Klinik","city":"München","zip":"80336","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Pius-Hospital; Klinik fuer Haematologie und Onkologie","city":"Oldenburg","zip":"26121","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"facility":"Sotiria Hospital","city":"Athens","zip":"11527","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Metropolitan Hospital; 2Nd Oncology Clinic","city":"Piraeus","zip":"185 47","country":"Greece","geoPoint":{"lat":37.94203,"lon":23.64619}},{"facility":"General Hospital of Thessaloniki Papanikolaou; Uni Pneumonology Dept.","city":"Thessaloniki","zip":"570 10","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Diavalkaniko Hospital","city":"Thessaloniki","zip":"57001","country":"Greece","geoPoint":{"lat":40.64072,"lon":22.93493}},{"facility":"Citta Ospedaliera; Divisione Oncologia Medica","city":"Avellino","state":"Campania","zip":"83100","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"facility":"IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A","city":"Napoli","state":"Campania","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"facility":"Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica","city":"Rome","state":"Lazio","zip":"00128","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1","city":"Rome","state":"Lazio","zip":"00152","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A","city":"Genoa","state":"Liguria","zip":"16132","country":"Italy","geoPoint":{"lat":44.40478,"lon":8.94439}},{"facility":"Az. Osp. Di Busto P.O. Di Saronno; U.O. Di Oncologia Medica","city":"Saronno","state":"Lombardy","zip":"21047","country":"Italy","geoPoint":{"lat":45.62513,"lon":9.03517}},{"facility":"A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii","city":"Pisa","state":"Tuscany","zip":"56124","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"Aichi Cancer Center Hospital; Respiratory Medicine","city":"Aichi","zip":"464-8681","country":"Japan","geoPoint":{"lat":32.51879,"lon":130.62158}},{"facility":"National Cancer Center Hospital East; Thoracic Oncology","city":"Chiba","zip":"277-8577","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"National Hospital Organization Shikoku Cancer Center; Thoracic Oncology","city":"Ehime","zip":"791-0280","country":"Japan"},{"facility":"National Hospital Organization Kyushu Cancer Center, Thoracic Oncology","city":"Fukuoka","zip":"811-1395","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Hyogo Cancer Center; Thoracic Oncology","city":"Hyōgo","zip":"673-8553","country":"Japan","geoPoint":{"lat":43.36667,"lon":144.43333}},{"facility":"Kanagawa Cardiovascular and Respiratory Center; Respiratory Medicine","city":"Kanagawa","zip":"236-0051","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"Yokohama Municipal Citizen'S Hospital; Respiratory","city":"Kanagawa","zip":"240-8555","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"Miyagi Cancer Center; Respiratory Medicine","city":"Miyagi","zip":"981-1293","country":"Japan","geoPoint":{"lat":26.62566,"lon":128.18236}},{"facility":"Okayama University Hospital; Respiratory and Allergy Medicine","city":"Okayama","zip":"700-8558","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"OSAKA CITY GENERAL HOSPITAL;Medical Oncology","city":"Osaka","zip":"534-0021","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Osaka International Cancer Institute; Thoracic Oncology","city":"Osaka","zip":"541-8567","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Shizuoka Cancer Center; Thoracic Oncology","city":"Shizuoka","zip":"411-8777","country":"Japan","geoPoint":{"lat":34.98333,"lon":138.38333}},{"facility":"National Cancer Center Hospital; Thoracic Medical Oncology","city":"Tokyo","zip":"104-0045","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"The Cancer Institute Hospital of JFCR, Respiratory Medicine","city":"Tokyo","zip":"135-8550","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"American University of Beirut - Medical Center","city":"Beirut","zip":"11-236","country":"Lebanon","geoPoint":{"lat":33.89332,"lon":35.50157}},{"facility":"Hotel Dieu de France; Oncology","city":"Beirut","zip":"16830","country":"Lebanon","geoPoint":{"lat":33.89332,"lon":35.50157}},{"facility":"Middle East Inst. of Health; Oncology","city":"Beirut","country":"Lebanon","geoPoint":{"lat":33.89332,"lon":35.50157}},{"facility":"Centenario Hospital Miguel Hidalgo","city":"Aguascalientes","zip":"20230","country":"Mexico","geoPoint":{"lat":21.88262,"lon":-102.2843}},{"facility":"Hospital Central Sur de Alta Especialidad Petróleos Mexicanos","city":"Mexico City","zip":"14140","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Centro Médico Abc the American British Cowdray Medical Center, I.A.P. - Centro de Cáncer","city":"Mexico City","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Amphia Ziekenhuis; Afdeling Longziekten","city":"Breda","zip":"4818 CK","country":"Netherlands","geoPoint":{"lat":51.58656,"lon":4.77596}},{"facility":"Catharina Ziekenhuis; Dept of Lung Diseases","city":"Eindhoven","zip":"5623 EJ","country":"Netherlands","geoPoint":{"lat":51.44083,"lon":5.47778}},{"facility":"Ziekenhuis St Jansdal; Dept of Lung Diseases","city":"Harderwijk","zip":"3844 DG","country":"Netherlands","geoPoint":{"lat":52.34167,"lon":5.62083}},{"facility":"Academisch Ziekenhuis Maastricht","city":"Maastricht","zip":"6202 AZ","country":"Netherlands","geoPoint":{"lat":50.84833,"lon":5.68889}},{"facility":"Antonius Ziekenhuis; Dept of Lung Diseases","city":"Nieuwegein","zip":"3435 CM","country":"Netherlands","geoPoint":{"lat":52.02917,"lon":5.08056}},{"facility":"Leyenburg Hospital; Pulmonology","city":"The Hague","zip":"2504 LN","country":"Netherlands","geoPoint":{"lat":52.07667,"lon":4.29861}},{"facility":"College of Medicine & Sciences, Sultan Qaboos University Hospital","city":"Muscat","zip":"P.O Box 35","country":"Oman","geoPoint":{"lat":23.58413,"lon":58.40778}},{"facility":"Fnsp Fdr Banska Bystrica; Dep of Pneumology&Ftizeology","city":"Banská Bystrica","zip":"975 17","country":"Slovakia","geoPoint":{"lat":48.73947,"lon":19.14932}},{"facility":"FNsP Bratislava, Nemocnica Ruzinov","city":"Bratislava","zip":"826 06","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Vychodoslovensky onkologicky ustav","city":"Košice","zip":"04001","country":"Slovakia","geoPoint":{"lat":48.71441,"lon":21.25802}},{"facility":"Inst. of Tb & Respiratory Diseases; Dep. of Oncology","city":"Nitra","zip":"949 88","country":"Slovakia","geoPoint":{"lat":48.30763,"lon":18.08453}},{"facility":"Hospital de Cruces; Servicio de Oncologia","city":"Barakaldo","state":"Vizcaya","zip":"48903","country":"Spain","geoPoint":{"lat":43.29639,"lon":-2.98813}},{"facility":"Hospital General Univ. de Alicante; Servicio de Oncologia","city":"Alicante","zip":"3010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Centro Oncologico MD Anderson International Espana","city":"Madrid","zip":"28033","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Clínico San Carlos; Servicio de Oncologia","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario La Paz; Servicio de Oncologia","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia","city":"Valencia","zip":"46010","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital Universitario Dr. Peset; Servicio de Oncologia","city":"Valencia","zip":"46017","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital Universitario Miguel Servet; Servicio Oncologia","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"Tawam Hospital; Medical Oncology Department","city":"Al Ain City","zip":"15258","country":"United Arab Emirates","geoPoint":{"lat":24.19167,"lon":55.76056}}]},"referencesModule":{"references":[{"pmid":"30177994","type":"DERIVED","citation":"Gridelli C, de Castro Carpeno J, Dingemans AC, Griesinger F, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial. JAMA Oncol. 2018 Dec 1;4(12):e183486. doi: 10.1001/jamaoncol.2018.3486. Epub 2018 Dec 13."},{"pmid":"26828788","type":"DERIVED","citation":"Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial. Cancer. 2016 Apr 1;122(7):1050-9. doi: 10.1002/cncr.29893. Epub 2016 Feb 1."},{"pmid":"21705281","type":"DERIVED","citation":"Gridelli C, Bennouna J, de Castro J, Dingemans AM, Griesinger F, Grossi F, Rossi A, Thatcher N, Wong EK, Langer C. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer. 2011 Nov;12(6):407-11. doi: 10.1016/j.cllc.2011.05.002. Epub 2011 Jun 25."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 485 participants were enrolled and randomized into the study. Of these, 475 participants were treated; 243 participants received bevacizumab plus standard of care (SoC) and 232 participants received SoC alone. The study was terminated 60 months after study start, as per protocol, but was not ended prematurely.","recruitmentDetails":"This phase 3b study was conducted across 16 different countries and enrolled 485 participants. Participants were 18 years or older and had locally recurrent or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC)","groups":[{"id":"FG000","title":"Bevacizumab + Standard of Care","description":"Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."},{"id":"FG001","title":"Standard of Care","description":"Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"245"},{"groupId":"FG001","numSubjects":"240"}]},{"type":"Treated Participants","achievements":[{"groupId":"FG000","numSubjects":"243"},{"groupId":"FG001","numSubjects":"232"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"245"},{"groupId":"FG001","numSubjects":"240"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"17"}]},{"type":"Trial termination by the Sponsor","reasons":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"19"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"190"},{"groupId":"FG001","numSubjects":"187"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Reason unknown","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Never Started","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent-to-treat population includes all randomized participants.","groups":[{"id":"BG000","title":"Bevacizumab + Standard of Care","description":"Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."},{"id":"BG001","title":"Standard of Care","description":"Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"245"},{"groupId":"BG001","value":"240"},{"groupId":"BG002","value":"485"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.5","spread":"9.61","lowerLimit":"26","upperLimit":"84"},{"groupId":"BG001","value":"61.8","spread":"9.29","lowerLimit":"35","upperLimit":"82"},{"groupId":"BG002","value":"61.6","spread":"9.44","lowerLimit":"26","upperLimit":"84"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"192"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"138"},{"groupId":"BG002","value":"293"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Overall survival (OS) was defined as the time from the date of randomization at first progression of disease to the date of death, regardless of the cause of death.","populationDescription":"Intent to treat population included all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)","groups":[{"id":"OG000","title":"Bevacizumab + Standard of Care","description":"Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."},{"id":"OG001","title":"Standard of Care","description":"Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"240"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.86","lowerLimit":"10.22","upperLimit":"13.67"},{"groupId":"OG001","value":"10.22","lowerLimit":"8.61","upperLimit":"11.93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The stratification factors for Log-Rank test and Hazard Ratio (HR) are the type of planned 2nd-line SoC treatment, the number of cycles of bevacizumab maintenance treatment prior to first PD and smoking status.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1044","statisticalMethod":"Stratified Log-Rank test","paramType":"Stratified Hazard Ratio","paramValue":"0.84","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.71","ciUpperLimit":"1.00"}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)","description":"PFS was defined as the time from start of treatment to the first event of death or PD. Tumor response was assessed by the IRF according to RECIST v1.1. Disease progression or PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS2 is defined as the time between randomization at PD1 and the date of PD2 or death, whichever occurs first. PFS3 is defined as the time between PD2 and the date of PD3 or death, whichever occurs first.","populationDescription":"Intent to treat population included all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)","groups":[{"id":"OG000","title":"Bevacizumab + Standard of Care","description":"Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."},{"id":"OG001","title":"Standard of Care","description":"Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"240"}]}],"classes":[{"title":"PFS 2","categories":[{"measurements":[{"groupId":"OG000","value":"5.45","lowerLimit":"4.21","upperLimit":"5.68"},{"groupId":"OG001","value":"3.98","lowerLimit":"3.38","upperLimit":"4.30"}]}]},{"title":"PFS 3","categories":[{"measurements":[{"groupId":"OG000","value":"4.01","lowerLimit":"2.86","upperLimit":"4.47"},{"groupId":"OG001","value":"2.60","lowerLimit":"2.33","upperLimit":"2.92"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"PFS 2: The stratification factors for Log-Rank test are the type of planned 2nd-line SoC treatment, the number of cycles of bevacizumab maintenance treatment prior to PD1 and the smoking status.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0573","statisticalMethod":"Stratified Log-Rank test","paramType":"Stratified Hazard Ratio","paramValue":"0.83","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.70","ciUpperLimit":"0.98"},{"groupIds":["OG000","OG001"],"groupDescription":"PFS 3: The stratification factors for Log-Rank test are the type of planned 2nd-line SoC treatment, the number of cycles of bevacizumab maintenance treatment prior to PD1 and the smoking status.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0045","statisticalMethod":"Stratified Log-Rank test","paramType":"Stratified Hazard Ratio","paramValue":"0.63","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.49","ciUpperLimit":"0.83"}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response According to RECIST v1.1","description":"The objective response is defined as complete response (CR) or partial response (PR) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR was defined as greater than or equal to (≥) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR.","populationDescription":"Intent to treat population included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)","groups":[{"id":"OG000","title":"Bevacizumab + Standard of Care","description":"Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."},{"id":"OG001","title":"Standard of Care","description":"Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"240"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"5.86","upperLimit":"12.21"},{"groupId":"OG001","value":"6.3","lowerLimit":"3.91","upperLimit":"9.50"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The stratification factors for Cochran-Mantel-Haenszel test are the type of planned 2nd-line SoC treatment, the number of cycles of Bevacizumab maintenance treatment prior to PD1 and the smoking status.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0810","statisticalMethod":"Stratified Cochran-Mantel-Haenszel test","paramType":"Estimated difference in response rate","paramValue":"0.0237","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.0156","ciUpperLimit":"0.0630"}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease Control According to RECIST v1.1","description":"The disease control rate is defined as CR or PR or stable disease (SD) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started for target lesions and the persistence of 1 or more non-target lesions.","populationDescription":"Intent to treat population included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)","groups":[{"id":"OG000","title":"Bevacizumab + Standard of Care","description":"Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."},{"id":"OG001","title":"Standard of Care","description":"Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"240"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.2","lowerLimit":"75.57","upperLimit":"84.36"},{"groupId":"OG001","value":"77.0","lowerLimit":"72.06","upperLimit":"81.41"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The stratification factors for Cochran-Mantel-Haenszel test are the type of planned 2nd-line SoC treatment, the number of cycles of Bevacizumab maintenance treatment prior to PD1 and the smoking status.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0218","statisticalMethod":"Stratified Cochran-Mantel-Haenszel test","paramType":"Estimated difference in Disease Control","paramValue":"0.0326","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.0288","ciUpperLimit":"0.0940"}]},{"type":"SECONDARY","title":"Duration of Response (DoR) According to RECIST v1.1","description":"Duration of response is defined as the time that measurement criteria are met for objective response (CR/PR) (whichever status is recorded first) until the first date of progression or death is documented. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \\< 10 mm. PR was defined as greater than or equal to ≥30 % decrease in sum of longest diameter of target lesions in reference to baseline sum longest diameter.","populationDescription":"Intent to treat population included all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)","groups":[{"id":"OG000","title":"Bevacizumab + Standard of Care","description":"Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."},{"id":"OG001","title":"Standard of Care","description":"Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"240"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.46","lowerLimit":"5.39","upperLimit":"8.54"},{"groupId":"OG001","value":"6.24","lowerLimit":"3.52","upperLimit":"6.83"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The stratification factors for Log-Rank test are the type of planned 2nd-line SoC treatment, the number of cycles of Bevacizumab maintenance treatment prior to PD1 and the smoking status.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0600","statisticalMethod":"Stratified Log-Rank test","paramType":"Stratified Hazard Ratio","paramValue":"0.29","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.09","ciUpperLimit":"0.90"}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.","populationDescription":"The safety population included all participants who had received at least one dose of any study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)","groups":[{"id":"OG000","title":"Bevacizumab + Standard of Care","description":"Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."},{"id":"OG001","title":"Standard of Care","description":"Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"243"},{"groupId":"OG001","value":"232"}]}],"classes":[{"title":"AEs","categories":[{"measurements":[{"groupId":"OG000","value":"97.5"},{"groupId":"OG001","value":"96.1"}]}]},{"title":"SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"51.9"},{"groupId":"OG001","value":"37.1"}]}]}]},{"type":"SECONDARY","title":"Time to Progression (TTP) According to RECIST v1.1","description":"The time to progression was defined as the time from baseline until disease progression as determined by the RECIST v1.1. TTP2 is defined as the interval between the day of randomization at PD1 and PD2. TTP3 is defined as the interval between the day of PD2 and PD3. PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.","populationDescription":"Intent to treat population included all randomized participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"90% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)","groups":[{"id":"OG000","title":"Bevacizumab + Standard of Care","description":"Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."},{"id":"OG001","title":"Standard of Care","description":"Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"240"}]}],"classes":[{"title":"TTP2","categories":[{"measurements":[{"groupId":"OG000","value":"5.55","lowerLimit":"4.86","upperLimit":"6.18"},{"groupId":"OG001","value":"4.21","lowerLimit":"3.75","upperLimit":"5.06"}]}]},{"title":"TTP3","categories":[{"measurements":[{"groupId":"OG000","value":"4.07","lowerLimit":"3.25","upperLimit":"4.63"},{"groupId":"OG001","value":"2.73","lowerLimit":"2.37","upperLimit":"3.06"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"TTP2: The stratification factors for Log-Rank test are the type of planned 2nd-line SoC treatment, the number of cycles of Bevacizumab maintenance treatment prior to PD1 and the smoking status.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0311","statisticalMethod":"Stratified Log-Rank test","paramType":"Stratified Hazard Ratio","paramValue":"0.79","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.65","ciUpperLimit":"0.95"},{"groupIds":["OG000","OG001"],"groupDescription":"TTP3: The stratification factors for Log-Rank test are the type of planned 2nd-line SoC treatment, the number of cycles of Bevacizumab maintenance treatment prior to PD1 and the smoking status.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0326","statisticalMethod":"Stratified Log-Rank test","paramType":"Stratified Hazard Ratio","paramValue":"0.69","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.52","ciUpperLimit":"0.92"}]},{"type":"SECONDARY","title":"Percentage of Participants Who Are Alive at Month 6, 12, and 18","description":"Percentage of participants who were alive at Month 6, 12 and 18 were reported.","populationDescription":"Intent to treat population included all randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"90% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Month 6, 12, 18","groups":[{"id":"OG000","title":"Bevacizumab + Standard of Care","description":"Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."},{"id":"OG001","title":"Standard of Care","description":"Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"240"}]}],"classes":[{"title":"Month 6","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.73","upperLimit":"0.82"},{"groupId":"OG001","value":"0.7","lowerLimit":"0.62","upperLimit":"0.72"}]}]},{"title":"Month 12","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.44","upperLimit":"0.54"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.39","upperLimit":"0.50"}]}]},{"title":"Month 18","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.31","upperLimit":"0.41"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.25","upperLimit":"0.36"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to data cut-off date 24 June 2016 (approximately 5 years)","description":"The safety population included all participants who had received at least one dose of any study drug.","eventGroups":[{"id":"EG000","title":"Bevacizumab + Standard of Care","description":"Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).","seriousNumAffected":126,"seriousNumAtRisk":243,"otherNumAffected":226,"otherNumAtRisk":243},{"id":"EG001","title":"Standard of Care","description":"Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).","seriousNumAffected":86,"seriousNumAtRisk":232,"otherNumAffected":215,"otherNumAtRisk":232}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":6,"numAtRisk":232}]},{"term":"Bone Marrow Failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Febrile Bone Marrow Aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Febrile Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":243},{"groupId":"EG001","numAffected":9,"numAtRisk":232}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":243},{"groupId":"EG001","numAffected":6,"numAtRisk":232}]},{"term":"Pure White Cell Aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Cardiac Failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Cyanosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Myocardial Ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Aplasia","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Tracheo-oesophageal Fistula","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Adrenal Insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Abdominal Pain Upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Duodenal Ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Gastrointestinal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Inguinal Hernia Strangulated","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Intestinal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Intestinal Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Large Intestine Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Mechanical Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Oesophageal Stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Pancreatitis Acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Pneumatosis Intestinalis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Small Intestinal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Small Intestinal Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Umbilical Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Upper Gastrointestinal Haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"General Physical Health Deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Mucosal Inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Non-Cardiac Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Performance Status Decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Sudden Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Bile Duct Obstruction","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Bile Duct Stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Liver Disorder","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Anal Abcess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Appendicitis Perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Bronchopulmonary Aspergillosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Device related Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Diarrhoea Infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Febrile Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Gastrointestinal Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Genital Herpes Simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Herpes Zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Lung Abcess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Lung Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Periorbital Abcess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":243},{"groupId":"EG001","numAffected":19,"numAtRisk":232}]},{"term":"Post Procedural Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Psoas Abcess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Respiratory tract Infection Bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Septic Shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Subcutaneous Abcess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Tracheitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Alcohol Poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Arterial Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Lumbar Vertebral Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Spinal Compression Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Upper Limb Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Blood Bilirubin Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Blood Creatinine Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Liver Function Test Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Lymphocyte Count Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"White Blood Cell Count Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Tetany","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Bone Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Flank Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Intervetebral Disc Protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Musculoskeletal Chest Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Musculoskeletal Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Pathological Fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Metastases to Adrenals","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Cerebral Infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Cerebral Ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Cerebrovascular Accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Ischaemic Stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Neuropathy Peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Parapalegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Peripheral Motor Neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Posterior Reversible Encephalopathy Syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Subarachnoid Haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Transient Ischaemic Attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Apathy","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Confusional State","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Suicide Attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Acute Kidney Injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Nephrotic Syndrome","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Prerenal Failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Renal Failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Renal Tubular Disorder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Uterine Haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Acute Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Bronchial Disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Chronic Obstructive Pulmonary Disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":243},{"groupId":"EG001","numAffected":3,"numAtRisk":232}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Interstitial Lung Disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":3,"numAtRisk":232}]},{"term":"Lung Disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Organizing Pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Pleural Effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":243},{"groupId":"EG001","numAffected":4,"numAtRisk":232}]},{"term":"Pneumonia Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":243},{"groupId":"EG001","numAffected":6,"numAtRisk":232}]},{"term":"Pulmonary Haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Pulmonary Thrombosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Respiratory Distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Erythema Multiforme","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Skin Toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Osteosynthesis","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":0,"numAtRisk":232}]},{"term":"Deep Vein Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Peripheral Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":243},{"groupId":"EG001","numAffected":1,"numAtRisk":232}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":54,"numAtRisk":243},{"groupId":"EG001","numAffected":69,"numAtRisk":232}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":243},{"groupId":"EG001","numAffected":10,"numAtRisk":232}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":243},{"groupId":"EG001","numAffected":20,"numAtRisk":232}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":243},{"groupId":"EG001","numAffected":9,"numAtRisk":232}]},{"term":"Lacrimation Increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":243},{"groupId":"EG001","numAffected":12,"numAtRisk":232}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":243},{"groupId":"EG001","numAffected":13,"numAtRisk":232}]},{"term":"Abdominal Pain Upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":243},{"groupId":"EG001","numAffected":14,"numAtRisk":232}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":64,"numAtRisk":243},{"groupId":"EG001","numAffected":49,"numAtRisk":232}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":90,"numAtRisk":243},{"groupId":"EG001","numAffected":72,"numAtRisk":232}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":84,"numAtRisk":243},{"groupId":"EG001","numAffected":61,"numAtRisk":232}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":243},{"groupId":"EG001","numAffected":26,"numAtRisk":232}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":243},{"groupId":"EG001","numAffected":40,"numAtRisk":232}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":68,"numAtRisk":243},{"groupId":"EG001","numAffected":61,"numAtRisk":232}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":243},{"groupId":"EG001","numAffected":16,"numAtRisk":232}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":71,"numAtRisk":243},{"groupId":"EG001","numAffected":73,"numAtRisk":232}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":243},{"groupId":"EG001","numAffected":14,"numAtRisk":232}]},{"term":"Mucosal Inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":243},{"groupId":"EG001","numAffected":22,"numAtRisk":232}]},{"term":"Oedema Peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":34,"numAtRisk":243},{"groupId":"EG001","numAffected":32,"numAtRisk":232}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":243},{"groupId":"EG001","numAffected":13,"numAtRisk":232}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":243},{"groupId":"EG001","numAffected":35,"numAtRisk":232}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":243},{"groupId":"EG001","numAffected":12,"numAtRisk":232}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":243},{"groupId":"EG001","numAffected":13,"numAtRisk":232}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":243},{"groupId":"EG001","numAffected":12,"numAtRisk":232}]},{"term":"Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":243},{"groupId":"EG001","numAffected":9,"numAtRisk":232}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":243},{"groupId":"EG001","numAffected":10,"numAtRisk":232}]},{"term":"Blood Creatinine Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":243},{"groupId":"EG001","numAffected":4,"numAtRisk":232}]},{"term":"Weight Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":42,"numAtRisk":243},{"groupId":"EG001","numAffected":24,"numAtRisk":232}]},{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":83,"numAtRisk":243},{"groupId":"EG001","numAffected":59,"numAtRisk":232}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":243},{"groupId":"EG001","numAffected":2,"numAtRisk":232}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":243},{"groupId":"EG001","numAffected":21,"numAtRisk":232}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":243},{"groupId":"EG001","numAffected":31,"numAtRisk":232}]},{"term":"Musculoskeletal Chest Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":243},{"groupId":"EG001","numAffected":8,"numAtRisk":232}]},{"term":"Musculoskeletal Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":243},{"groupId":"EG001","numAffected":18,"numAtRisk":232}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":243},{"groupId":"EG001","numAffected":18,"numAtRisk":232}]},{"term":"Pain in Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":243},{"groupId":"EG001","numAffected":16,"numAtRisk":232}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":243},{"groupId":"EG001","numAffected":13,"numAtRisk":232}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":243},{"groupId":"EG001","numAffected":16,"numAtRisk":232}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":243},{"groupId":"EG001","numAffected":23,"numAtRisk":232}]},{"term":"Neuropathy Peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":243},{"groupId":"EG001","numAffected":16,"numAtRisk":232}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":243},{"groupId":"EG001","numAffected":8,"numAtRisk":232}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":243},{"groupId":"EG001","numAffected":12,"numAtRisk":232}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":243},{"groupId":"EG001","numAffected":15,"numAtRisk":232}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":243},{"groupId":"EG001","numAffected":23,"numAtRisk":232}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":243},{"groupId":"EG001","numAffected":40,"numAtRisk":232}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":243},{"groupId":"EG001","numAffected":13,"numAtRisk":232}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":56,"numAtRisk":243},{"groupId":"EG001","numAffected":56,"numAtRisk":232}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":53,"numAtRisk":243},{"groupId":"EG001","numAffected":20,"numAtRisk":232}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":243},{"groupId":"EG001","numAffected":11,"numAtRisk":232}]},{"term":"Pleural Effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":243},{"groupId":"EG001","numAffected":15,"numAtRisk":232}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":55,"numAtRisk":243},{"groupId":"EG001","numAffected":41,"numAtRisk":232}]},{"term":"Dermatitis Acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":243},{"groupId":"EG001","numAffected":8,"numAtRisk":232}]},{"term":"Dry Skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":243},{"groupId":"EG001","numAffected":22,"numAtRisk":232}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":243},{"groupId":"EG001","numAffected":17,"numAtRisk":232}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":243},{"groupId":"EG001","numAffected":14,"numAtRisk":232}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":243},{"groupId":"EG001","numAffected":46,"numAtRisk":232}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":243},{"groupId":"EG001","numAffected":25,"numAtRisk":232}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"888-6821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Jordan","Qatar"]},"interventionBrowseModule":{"meshes":[{"id":"D000068258","term":"Bevacizumab"},{"id":"D000077143","term":"Docetaxel"},{"id":"D000069347","term":"Erlotinib Hydrochloride"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}